CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).
  
  OVERVIEW OF ACTIVITY
  Epithelial OC accounts for approximately 90% of malignant ovarian neoplasms, and this makes it the leading cause of death from gynecologic cancer in the United States. The most significant recent development in OC has been the introduction of PARP inhibitors into the therapeutic milieu. Important advances in the collective understanding of PARP inhibition as a mechanism to combat the development and progression of OC have led to the FDA approval of multiple PARP inhibitors in a number of clinical settings. The availability of PARP inhibitors has significant ramifications for practicing oncologists, who need to confront a variety of practical issues with regard to the safe and effective use of these agents.
  
  To bridge the gap between research and patient care, this video presentation by Dr David O’Malley uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of OC with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing in OC, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
  • Recognize the recent FDA approval of olaparib as maintenance therapy for patients with advanced OC with a BRCA mutation after first-line platinum-based chemotherapy, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Appreciate available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with OC to effectively integrate these agents into routine clinical practice.
  • Consider published research findings with PARP inhibitors as maintenance therapy for patients with recurrent, platinum-sensitive OC, and develop strategies to identify appropriate candidates for this approach.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the treatment of OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy or immunotherapy, and refer appropriate and interested patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Presenting Faculty Member
  
  David M O’Malley, MD
  Professor
  Division Director, Gynecologic Oncology
  Co-Director, Gynecologic Oncology Phase I Program
  The Ohio State University and The James Cancer Center
  Columbus, Ohio
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GOG Foundation Inc, Janssen Biotech Inc, Myriad Genetic Laboratories Inc, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, ImmunoGen Inc, Partnership for Health Analytic Research LLC, Tesaro, A GSK Company; Contracted Research: Agenus Inc, Ajinomoto, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, EMD Serono Inc, Ergomed PLC, Exelixis Inc, Genentech, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Ludwig Institute for Cancer Research Ltd, Novartis, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.
  
  Project Steering Committee Members
  
  Michael J Birrer, MD, PhD
  Director, O’Neal Comprehensive Cancer Center
  Professor of Medicine/Hematology and Oncology
  Evalina B Spencer Chair in Oncology
  The University of Alabama at Birmingham
  Birmingham, Alabama
  
  No relevant conflicts of interest to disclose.
  
  Robert L Coleman, MD
  Professor and Executive Director
  Cancer Network Research
  Ann Rife Cox Chair in Gynecology
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Contracted Research: AbbVie Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GamaMabs Pharma, Genentech, Genmab, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Gottfried E Konecny, MD
  Professor-in-Residence
  Division of Hematology-Oncology
  Department of Medicine, David Geffen School of Medicine
  UCLA Medical Center
  Santa Monica, California
  
  No relevant conflicts of interest to disclose.
  
  Ursula Matulonis, MD
  Chief, Division of Gynecologic Oncology
  Brock-Wilson Family Chair
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee and Consulting Agreement: Novartis.
  
  Kathleen Moore, MD
  The Virginia Kerley Cade Endowed Chair in Cancer Development
  Associate Director, Clinical Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, ImmunoGen Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Samumed, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics, Roche Laboratories Inc.
  
  Angeles Alvarez Secord, MD, MHSc
  Professor, Duke Cancer Institute
  Duke University Health System
  Durham, North Carolina
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Immutep Ltd, Incyte Corporation, Merck, Roche Laboratories Inc, Seattle Genetics, Tesaro, A GSK Company.
  
  Robert M Wenham, MD, MS
  Chair and Director of Research, Department of Gynecologic Oncology
  Senior Member, Program of Chemical Biology and Molecular Medicine
  Professor, Department of Interdisciplinary Oncology, USF
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: Amgen Inc, Clovis Oncology, Genentech, Merck, Mersana Therapeutics, Ovation Diagnostics, TapImmune Inc, Tesaro, A GSK Company; Consulting Agreement: Merck; Data and Safety Monitoring Board/Committee: Tesaro, A GSK Company; Ownership Interest: Ovation Diagnostics; Speakers Bureau: Clovis Oncology, Genentech, Janssen Biotech Inc, Tesaro, A GSK Company.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro, A GSK Company.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: December 2019
  Expiration date: December 2020